The success reported for the treatment of superficial skin carcinomas by photodynamic therapy with topical application of the photosensitizer precursor 5-aminolevulinic acid has therapeutic implications for the treatment of other sldn disorders. This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm. We present results from 15 patients with a total of 42 plaques and show that the characteristic fluorescence emission of protoporphyrin IX increases in intensity within the 6-h period following application of 5-aminolevulinic acid. suggesting that there is a potential S Ln ce Kennedy ef al (1990) first de sc ribe d the treatme nt of superficial skin ca rcinomas by photodynamic therapy (PDT), usiJl g top ica l app li ca tion of the photosensiti ze r precursor 5-aminolevu linic acid (ALA), other cente rs (Wolf ef ai, 1993; Ca irndufF ef ai, 1994; Svanbel'g ef ai, 1994; Fij~1I1 ef ai , 1995) have reported the e fFectiveness of this type of treatment. The perceived advantages of ALA-PDT, notably the locali zed and sh ort-tcrm photosensiti v ity, have le d to con side ration of the teclmique for other sites of malignan cy or pre malignan cy su ch as Barrett's eso phagus · (Barr ef ai , 1995) and for nonmalignant co nditi o ns that involve on ly the most superficia l tiss ue layer, such as the endom etrial surfa ce of the uterus (Gannon el ai , 1995).
The success reported for the treatment of superficial skin carcinomas by photodynamic therapy with topical application of the photosensitizer precursor 5-aminolevulinic acid has therapeutic implications for the treatment of other sldn disorders. This paper describes the accumulation of the photosensitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emission induced by low-intensity laser excitation at 488 nm. We present results from 15 patients with a total of 42 plaques and show that the characteristic fluorescence emission of protoporphyrin IX increases in intensity within the 6-h period following application of 5-aminolevulinic acid. suggesting that there is a potential S Ln ce Kennedy ef al (1990) first de sc ribe d the treatme nt of superficial skin ca rcinomas by photodynamic therapy (PDT), usiJl g top ica l app li ca tion of the photosensiti ze r precursor 5-aminolevu linic acid (ALA), other cente rs (Wolf ef ai, 1993; Ca irndufF ef ai, 1994; Svanbel'g ef ai, 1994; Fij~1I1 ef ai , 1995) have reported the e fFectiveness of this type of treatment. The perceived advantages of ALA-PDT, notably the locali zed and sh ort-tcrm photosensiti v ity, have le d to con side ration of the teclmique for other sites of malignan cy or pre malignan cy su ch as Barrett's eso phagus · (Barr ef ai , 1995) and for nonmalignant co nditi o ns that involve on ly the most superficia l tiss ue layer, such as the endom etrial surfa ce of the uterus (Gannon el ai , 1995) .
T he use of photodynamic therapy to treat pso riasi s was first reported in 1937; usin g systemic administration of hematoporph yrin in co mbinatio n with ultraviolet rad iation, Si lver reported improvement in se ven patients (Si lver, 1937) . Subsequent worke rs have a lso reporte d the efficacy of he mato porphyrin s administered Manuscrip t rcceivcd Dccember 18. 1995; revi sed March 26, 1996 ; accepted for publication March 27, 1996 . R.eprint requests to: Dr. Mark R. Stringer, R.esearch School of Medicine, Medical Physi cs. Cente r for Photobiology and Photodynami c T herapy, University of Lccds, We llcomc Win g, Lceds Gcnera l In f,rmary, Leeds LSl 3EX. UK.
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I Barr H. Dix T. R.oberts D, Shepha rd N: P'hotodynami c therapy for hi gh grade dyspla sia and adenocarcinomma in Barrett's oesophagus usin g photo scnsitization with aminol cvulilli c acid. Las Med Sci 9: 2 19,1995 (abstr.) for superficial photodynamic therapy. The rate of increase and maximum intensity of fluorescence emission was not directly related to the applied quantity of the precursor. The variability of the fluorescence intensity was as great between plaques at different sites on the same patient as between different patients. Also. the effect of plaque occlusion following application appeared insignificant. Although there was only limited enhancement of emission from areas of sldn surrounding the plaque. a significant build-up of sensitizer was detected after several days in some areas of psoriasis that received no application. Key words: jlllOl'eSCellcelpilOtosellsitiz atiOll, J I,west Demratol 107:76-81, 1996 systemi call y follow e d b y 630-nm ilJumination (Berns el ai, 1984) or topica ll y using ultraviolet or visible radi ation (MefFert el ai, 1989) . The resu ltant prolonged photosensitivity was recogni zed as the major limi tation of system ic administration for thi s form of treatment. Rece ntly, Boehncke ef al (1994a) reported th e d ec rease in Auorescen ce e mission (photobleachin g) of the photosensiti zer Photosal1-3 induced by illumination at 630 nm after topical appUcation to psoriatic plaques . The same author (1994b) h as subsequ entl y d e monstrated the possibility of topica l ALA-PDT in therapy by ac hieving clearance comparabl e to that with dithranol in chronic plaque-stage psoriasis in three patients. It had pre viously been observed (Ke nn e dy and Pottie r, 1992) th 'lt top ica l ALA-induced protoporphyrin IX (PpIX) was confin e d to areas of pso riasis , but the clinica l res ponse to illumination was variable.
In order to ma x; mize PDT e ffe ctiveness afte r app lication of ALA, illumination of the treatment area sh ou ld occur at a time of sufficiently in c reased concentration of the endogeno us photosensitizer. The accumu lation of intracellular PpIX is governed b y the heme biosynth etic pathway and is therefore depend e nt upon the d iffusion rate of exogenous ALA throughout the abnormal e pitheliUln and by the rate of h e m e formation. it has b een shown (Loh eI ai , 1993 ) that difFere nt types of tissue m etabolize the sensitizer at difFerent rates and to difFe re nt d egrees. In the treatment of superficia l ski n carcinomas reported to date, time inte rval s of 3 to 20 h have been adopted b etween ALA application andilJumination . With ALA in com bimltion with th e iron c helator desferrioxamine, favorab le results were re porte d (Fijan cl ai , 1995) . . locali zation ofPpIX to the area of ALA application. T he resul ts are used to assess the potential for superficial PDT and establish appropriate treatment conditions.
MATERIALS AND M ETH ODS
Experimental Apparatus Fluorcsccn cc was induccd with the 488-nm o utput from an argon-ion lascr deli vc red to the surf.,ce of the skin via a 600-JLm-core optical fi bcr at a power of4 mW. A second fiber was used to coll cct the cmitted li ght, which was fi ltered (OG 530, lo ng-pa ss) to block the sca ttered lascr radi ation and dcli vered to thc entra nce slit of a singlc-chann c l optica l spectrum analyzcr (Rces Instruments Ltd, Goda lming, UK). T hc delivcry and detector fibcrs arc arranged norma l to thc skin surface in a hand-held probe that analyzes a circu lar area of 0.1 cm 2 , resultin g in a locali zed irradi ance of 40 m W cm -2 • The spectru m ana lyzcr cmploys a rcvolving diffraction g rating to capture a completc spectrum (450-900 nm) every 80 m s. w hj ch is regi stered by a red-scnsitive ph otomu lti pljer tu be . T lu s ensu rc s d,at nonlinearity of dctector responsc is avo ided, bu t in o rde r fo r an adeq uate signal-to-noise ratio to be achjeved, ,~----5!: using 50 m g cm -2 of ALA prepa ration . Error /Ja rs , m ea n ± SO of th ree measurements fro m cl osely sp" ccd points w ithin the sa m e pl"q ll c. Patients T hese stud ies were approv ed by the ethi ca l commi ttee of th e h osp ital. Co nsec utive patients w ith chro ni c plaqu e pso ri asis were n!cruited , and each gave w ri tten info rmed consen t. All had been trea ted previously with topica l th e rap)' (tar, dithranol , or calci potrio l). often in combm aoon with UV13 phototherapy. N o n e was und ergoing treatm ent at the time of recrui tm ent o r had rece ived phototherapy durin g 4 m o nths prior to the study. EmoU.ient (aq ueo us crea m) o nl y was used fo r 2 weeks before topi cal ALA.
In 10 pa tie nts (group '1) , e ithe r three o r fo ur sq uares (2 X 2 cm) were defined o n eac h th at were withi n o r overl appin g an area of psoriasis. A tota l of 32 sites were studied, of w hi ch 5 were bi opsied. T he plaques were located upon the elbows (4 patients). forearm (4), ba ck (l), and thig h ( 1). No formal assess m en t was m ade of plaqu e thickness. ALA (Sigma C hemi ca l Co. Ltd , UK), dissolved (20'1., by w eight) in a pro pri eta ry o il-i n-water e mulsion (Unguentul11 M erck. W hi tehall Laboratories Ltd, UK). w~s ap pli ed to th e chosen sites in qua ntities <:~ 50, 100. o r 200 m ? fo r 1 h. T IllS corresponds to 12.5, 25, and 50 m g cm -o f cream. respective ly. Flu Ol'esce n ce spectra were recorded fi,o lll these sites at ti m e po ints between 83 and 360 min. In four of t he pa tients. flu o rescence spectra were taken after 4 d. Tn twO patie nts m eas urem en ts we re mad e (at around 4 h) tra n svers~l y :,cross th e plaque and beyond in o rder to determine the degree of locahzaoon of t he accumula ted ppl X to the arca of applicatio n . . Five pati e nts w ith symm etrical pl aq ue pso ria sis at the e lbow s (group 2) had a test site (2 X 2 cm) defined w ithin each plaqu e . ALA 20% in U n g u el1tum Merck wa s app lied at a quantity of 50 m g cm -2 to both squares.
One was th en covered with a tran sparent po lythene dressing (Tegaderm , 3M Health Care Ltd, Loughbol"Ough , UK) to form an occluded site and resi du al ALA wa s removed fi'o lll the n o n occl uded site afte r ' 1 h. Flu orescence meas urern ents were made fro m 80 to 360 mi.ll after application ; o n the occlud ed sites the m eas urem ents were made thro ug h th e po lythene .
Data Analysis Figure 1 illustrates th e procedure involved in obtaini~~ the ph otosensitizer fluorescence spectrum . In thi s exa m ple. 12.5 m g cmof the ALA preparation was app lied to a plaque upon the elbow. The fluores cence speco'a were recorded at times rangin g from 85 to 280 min after app li ca tion and then aga.in afte r 4 d . It is clear fro m the spectra shown that the tissue autofluorescence dominated th e recorded sig nal. Also. although th e experimen tal pa ram eters rem ained constant for all m easurel11 cncs. there \vas considerable variation in the intensity of autofluorescen ce, even for re peated measurements upon the sam e plaqu e , but b y an al ysis of the shape of an "veraged autofl uorescence spectrum (obta in ed from measurem ent points upo n at leas t o ne area of plaque n ot exposed to ALA, on each patient), a backgrou nd correctio n cou ld be m ade to a\J ow the subtractio n of the autofl u orescence o utpu t fro m the tota l. T ill S yield ed the ph otosensitizer fluorescence spectru m . T h e inrcnsity of the 488-n m excitation was recorded prio r to each measuremen t and va l;cd by up to :!: 5% from the m ean . T he spectra were th erefore n o rmali zed for laser powe r va ri atio ns after th e b ackgro und co rrection. A pl ot of th e h eigh t of th e 635-1U11 emission peak as a fun ction of timc afte r application demonstrated the b uild-u p of Pp IX w ithin the area of analysis. T h e error bars represen t th c sta ndard deviation of three readings taken fro l1l close ly spaced points within the same plaqu e. T he major con tribu tio n to th e crror is a resul t of subtractio n of th c autofluorescent background. A secon d m easurem e nt at the sa m e point. perform ed immediately after th e first. ind icates that th e peak fluoresce nce intensity of PpIX is red uced by approxim ately 5%, a cOlISequcnce of SClISitizer photo-oxidation d uring the period of m easurem ent. None of the data presented here. however. involved such a repetition. and we have not. therefore. attempted to apply a photobleaching cOITection to individual m easurements.
RESULTS
Evidence of PpIX Accumulation T h e Auorescen c~ in.tensity from ALA-induced PplX in creased with time after appb cabon for all patients studied . Figure 2 shows the compl ete set of results fro m The Effect of Using Differe nt Quantities of ALA Is Not Significant Figure 3 shows the results from 5 of th e 10 patients up o n which the three different quantities of ALA were applied. T h ese graphs include the data points from patients that exhibited the grea test extrem es of Auorescen ce in te nsiry. T he plots that are o mitted (fo r clariry) ail li e within these extrem es. For each con centratio n of ALA used there was a signifi ca nt increase in PpIX Auorescence, but the intensity of Auoresccn ce obtained with o nly 50 m g of ALA prep arati o n was mu ch more variable between patients th an that induced by th e use of 100 or 200 m g .
The Effect of Plaque Occlusion Is Not Significant The effect upon th e ALA-ind uced PplX accumulation of plaque occlusion by applica ti on of a polythene dressing' is shown in Fig 4 . Only in one patient did there appear to be ev id ence of a signifi cant difference in Au orescence intensity between occluded and non occluded si tes over the whole period of analysis.
Enhanced PpIX Accumulation in Plaque, Compared to Adjacent Skin Figure 5 sh o w s the res ults of m eas urem ents made transversely across an area of ski n that contained a small plaque 4.3 h after application of crea m. The intensity of th e 635-nm peak is shown to be almost equ al across the p laque, with a much lower « 25%) emission from the skin m argin tha t had received ALA. Away £i'om the area of application, the sig nal was reduced to less than 5% of the maximum .
Evidence ofPpIX in Untreated Plaque The spectra shown in Fig 6 are derived from a patient in group 1. M easure m ents were made upon sites that included p laque treated w ith ALA, adjacent nontreated plaque, remote plaque, and areas of normal skin. These sp ectra show that over the first few hours, only those sites receiving ALA displayed a PpIX emjssion. After 4 d, however, not only ha d th e Auorescence intensiry doubled at the sites of application, but th ere was also a significant emiss ion in non treated points on th e same p laque as w ell as in a plaque separated (> 15 cm) from those treated. The sig na l obtained from normal skin was sma ll er than th e treated plaques by at leas t a factor of 1 00 , and 50 times smaller than that in the remote plaque .
DISCUSSION
It sho uld be emphasized that these are m acroscopic measurements that register the av erage Auorophor distribution within the 0.1 -cm 2 area of ana lysis. T he microscopic distribution of photosensitizer and tissue Auorescen ce is not resolved by tllis tedl.lliqu e. The us e of 488-nm excitation limits the ana lysis to the e pidermis, and so w e can conclude from these m eas urem ents that the synthesis of PplX proceeds effectively in p laqu e psoriasis after topical application of ALA. In all examp les, the re was a steady bui ld-up in Auorescen ce inten sity during the fust 4 h , with instances of continued PpIX accumulation up to 5 h and beyo nd . There were con siderable variations in bo th the rate of increase and the maximum intensity of Auorescen ce achi eved . These va riations were as great between differen t si tes on th e same patient as between different pati ents . T h e PpIX accumulation was not significantly dependent upon the app lied quantity of ALA, althoug h in the sample studied (gro up 1) th e small est v ariation in data points was obtained with a concentrati o n of 25 mg cm -2 , When the patient and site variations are taken into account, th e effect of occluding the p laque fo llowing ALA application also appears not to be significa nt, implying that occlusion do es not enhance ALA penetration . Such variations also preclude any acc urate predi ction of PpIX accumulation at different sites upon th e body, althou g h the data from this study do suggest that the m ost intense fluorescence is o btained fro m plaques located upon the elbows. T he five biopsy sa mples are currently undergoin g analysis by fluores cence microscopy in order to esta blish the e pidermal di stribution of PpIX.
T h ere was a m easu rable PpIX content in th e b o rd er of skin immediately adj acent to a plaque when both received ALA. Skin not covered by cream showed a much less sig nifi cant enhancem ent. It is likely that the proximity of the po int of m easurem ent to th e plaque is the dominant factor in this e fFect.
Results o btained fi:om on e patie nt show not only that th ose plaques treated with ALA di splay an enhanced PpIX content after severa l days, but also that remote plaques display significant fluorescence. Although the m agnitude of effect in this individual is the g reatest that h as been m eas ured to date, the p ersistence and distribution of th e fluorescen ce has been registered in other patients and raises some important qu es tions regarding this type of dru g application . The separatio n of the sites involved and th e sup ervisio n of the patient over the initial period after appli cation (during which most if not all of the ALA is absorbed) indicates that the ALA is not tran sferred to the remote sites by direct contact, which implies a biochemical transport mechanism either for th e photosensitizer or the precursor. T he bloodstream is the m ost o bv ious candidate for sys temic distribution of either of these agents; a program of blood sampling over an exten ded time period afte r application of ALA IS now in progress.
T he intensity of fluorescen ce emissio n reported in tlus stud y is comparable to, and in man y cases greater than , m eas urem ents we have m ade upon areas of superficial skin carcinoma . This indicates that PDT h as th e potential to be a ben eficia l therapy for plaque psoriasis. Using these findings, we h ave e stablished a treatment protocol that involves usin g 100 mg of 20')1" ALA in Unguentum Merck with n o occl usion of the site and with the subs eq uent PDT illumination to proceed at a time point of 3 .5 h after application. Lack of occlusion allows the possibility of unsupervised application of th e crea m by th e patient several hours before attending the clinic. A clini cal trial is und erwa y, involving the sup erfi cia l illumi-ALA-INDUCED Ppl X IN PSOR.l AS IS 81 nation of selected areas of plaque psoriasis using a broad-spectrum light source . 
